


## CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

1. (Currently Amended) A compound having the formula



wherein

X is S, SO or SO<sub>2</sub>;

R<sup>1</sup> is a ~~5- or 6-membered monocyclic, hetero- or homocyclic, saturated or unsaturated~~ pyridyl ring structure optionally substituted with one or more substituents selected from the group consisting of

halogen, CN, (1C-4C)fluoroalkyl, nitro, (1C-4C)alkyl, (1C-4C)alkoxy and (1C-4C)fluoroalkoxy;

R<sup>2</sup> is 2-nitrophenyl, 2-cyanophenyl, 2-hydroxymethyl-phenyl, ~~pyridin-2-yl, pyridin-2-yl-N-oxide,~~ 2-benzamide, 2-benzoic acid methyl ester or 2-methoxyphenyl;

R<sup>3</sup> is H, halogen or (1C-4C)alkyl;

R<sup>4</sup> is H, OH, (1C-4C)alkoxy, or halogen;

$R^5$  is H, OH, (1C-4C)alkoxy,  $NH_2$ , CN, halogen, (1C-4C)fluoroalkyl,  $NO_2$ , hydroxy(1C-4C)alkyl,  $CO_2H$ ,  $CO_2(1C-6C)alkyl$ , or

$R^5$  is  $NHR^6$ , wherein  $R^6$  is (1C-6C)acyl optionally substituted with one or more halogens,  $S(O)_2(1C-4C)alkyl$ , or  $S(O)_2aryl$  optionally substituted with (1C-4C)alkyl or one or more halogens, or

$R^5$  is  $C(O)N(R^8, R^9)$ , wherein  $R^8$  and  $R^9$  each independently are H, (3C-6C)cycloalkyl, or  $CH_2R^{10}$ , wherein  $R^{10}$  is H, (1C-5C)alkyl, (1C-5C)alkenyl, hydroxy(1C-3C)alkyl, (1C-4C)alkylester of carboxy(1C-4C)alkyl, (1C-3C)alkoxy(1C-3C)alkyl, (mono- or di(1C-4C)alkyl)aminomethyl, (mono- or di(1C-4C)alkyl)aminocarbonyl, or a 3-, 4-, 5- or 6-membered monocyclic, ~~homo- or heterocyclic~~, homocyclic, aromatic or non-aromatic ring, ~~or  $R^8$  and  $R^9$  form together with the N a heterocyclic 5- or 6-membered saturated or unsaturated ring optionally substituted with (1C-4C)alkyl;~~

or a salt thereof.

2. (Currently Amended) The compound according to claim 1, wherein,

$R^1$  is a ~~5- or 6-membered monocyclic, hetero- or homocyclic, saturated or unsaturated~~ pyridyl ring structure optionally substituted with one or more substituents selected from the group consisting of halogen, CN,  $CF_3$ , nitro, methoxy, trifluoromethoxy and methyl;

$R^2$  is 2-nitrophenyl, 2-cyanophenyl, 2-hydroxymethyl-phenyl, ~~pyridin 2-yl, pyridin 2-yl N-oxide,~~ 2-benzamide, 2-benzoic acid methyl ester or 2-methoxyphenyl;

$R^3$  is H, halogen or (1C-2C)alkyl;

$R^4$  is H or F.

3. (Currently Amended) The compound according to claim 2, wherein,

$R^5$  is H, OH, (1C-4C)alkoxy, CN, halogen, (1C-4C)fluoroalkyl,  $NO_2$ , hydroxy(1C-4C)alkyl,  $CO_2(1C-6C)$ alkyl, or

$R^5$  is  $NHR^6$ , wherein  $R^6$  is (1C-6C)acyl optionally substituted with one or more halogens,  $S(O)_2(1C-4C)$ alkyl, or  $S(O)_2$ aryl optionally substituted with (1C-4C)alkyl or one or more halogens, or

$R^5$  is  $C(O)N(R^8, R^9)$ , wherein  $R^8$  and  $R^9$  each independently are H, (3C-6C)cycloalkyl, or  $CH_2R^{10}$ , wherein  $R^{10}$  is H, (1C-5C)alkyl, (1C-5C)alkenyl, hydroxy(1C-3C)alkyl, (1C-4C)alkylester of carboxy(1C-4C)alkyl, (1C-3C)alkoxy(1C-3C)alkyl, (mono- or di(1C-4C)alkyl)aminomethyl, (mono- or di(1C-4C)alkyl)-aminocarbonyl, or a 3-, 4-, 5- or 6-membered monocyclic, ~~homo- or heterocyclic~~, homocyclic, aromatic or non-aromatic ring, ~~or  $R^8$  and  $R^9$  form together with the N a heterocyclic 5- or 6-membered saturated or unsaturated ring optionally substituted with (1C-4C)alkyl.~~

4. (Currently Amended) The compound according to claim 3, wherein,

$R^3$  is H or halogen;

$R^4$  is H;

$R^5$  is H, OH, (1C-4C)alkoxy, CN, F, Cl,  $CF_3$ ,  $NO_2$ , hydroxy(1C-4C)alkyl,  $CO_2(1C-6C)$ alkyl, or

$R^5$  is  $NHR^6$ , wherein  $R^6$  is (1C-3C)acyl optionally substituted with one or more halogens or

$R^5$  is  $C(O)N(R^8, R^9)$ , wherein  $R^8$  and  $R^9$  each independently are H, (3C-5C)cycloalkyl, or  $CH_2R^{10}$ , wherein  $R^{10}$  is H, (1C-5C)alkyl, (1C-5C)alkenyl, hydroxy(1C-3C)alkyl, (1C-2C)alkylester of

carboxy(1C-2C)alkyl, (1C-3C)alkoxy(1C-3C)alkyl, (mono- or di(1C-4C)alkyl)aminomethyl, (mono- or di(1C-4C)alkyl)aminocarbonyl, or (3C-5C)cycloalkyl, ~~or a 5 membered heterocyclic ring.~~

5. (Currently Amended) The compound according to claim 4, wherein,

X is S or SO<sub>2</sub>;

R<sup>2</sup> is 2-nitrophenyl, 2-hydroxymethyl-phenyl, 2-benzamide, 2-methoxyphenyl, or 2-cyanophenyl ~~or pyridin-2-yl;~~

R<sup>3</sup> is H or F;

R<sup>5</sup> is H, OH, (1C-2C)alkoxy, CN, F, Cl, CF<sub>3</sub>, NO<sub>2</sub>, hydroxy(1C-4C)alkyl, CO<sub>2</sub>(1C-4C)alkyl, or

R<sup>5</sup> is NHR<sup>6</sup>, wherein R<sup>6</sup> is formyl, acetyl, fluoroacetyl, difluoroacetyl, or trifluoroacetyl, or

R<sup>5</sup> is C(O)N(R<sup>8</sup>,R<sup>9</sup>), wherein R<sup>8</sup> is H, and R<sup>9</sup> is H, cyclopropyl or

R<sup>9</sup> is CH<sub>2</sub>R<sup>10</sup>, wherein R<sup>10</sup> is H, (1C-2C)alkyl, hydroxy(1C-2C)alkyl, methoxy(1C-2C)alkyl, or cyclopropyl.

6. (Currently Amended) The compound according to claim 5, wherein,

X is S;

R<sup>1</sup> is ~~3,5-difluorophenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, pyrimidin-4-yl, pyrazin-2-yl, 3-fluorophenyl, 3-cyanophenyl, or 3-nitrophenyl;~~ pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, pyrimidin-4-yl, pyrazin-2-yl, 3-fluorophenyl, 3-cyanophenyl, or 3-nitrophenyl;

R<sup>2</sup> is 2-nitrophenyl, 2-hydroxymethyl-phenyl, 2-methoxyphenyl, or 2-cyanophenyl ~~or pyridin-2-yl;~~

R<sup>3</sup> is H;

R<sup>5</sup> is OH, (1C-2C)alkoxy, CN, CF<sub>3</sub>, NO<sub>2</sub>, hydroxy(1C-4C)alkyl, CO<sub>2</sub>(1C-4C)alkyl, or NHR<sup>6</sup>, wherein R<sup>6</sup> is formyl, acetyl, fluoroacetyl, difluoroacetyl, or trifluoroacetyl.

7. (Currently Amended) The compound according to claim 6, wherein,

R<sup>1</sup> is ~~3,5-difluorophenyl~~, pyridin-2-yl, or pyridin-3-yl, ~~pyrimidin-5-yl, pyrimidin-4-yl, or pyrazin-2-yl;~~

R<sup>2</sup> is 2-nitrophenyl, or 2-hydroxymethyl-phenyl;

R<sup>5</sup> is OH, (1C-2C)alkoxy, CN, hydroxy(1C-4C)alkyl, or NHR<sup>6</sup>, wherein R<sup>6</sup> is formyl, acetyl, fluoroacetyl, difluoroacetyl, or trifluoroacetyl.

8. (Currently Amended) The compound according to claim 7, wherein,

R<sup>1</sup> is ~~3,5-difluorophenyl~~, pyridin-2-yl, or pyridin-3-yl, ~~pyrimidin-5-yl, or pyrimidin-4-yl;~~

R<sup>2</sup> is 2-nitrophenyl;

R<sup>5</sup> is OH, (1C-2C)alkoxy, CN, or NHR<sup>6</sup>, wherein R<sup>6</sup> is formyl, acetyl, fluoroacetyl, difluoroacetyl, or trifluoroacetyl.

9. (Currently Amended) The compound according to claim 8 selected from the group consisting of

~~6-Methoxy-3-(2-nitro-phenylsulfanyl)-1-pyrimidin-5-ylmethyl-1H-indole,~~ 3-(2-Nitro-phenylsulfanyl)-1-pyridin-2-ylmethyl-1H-indole-6-carbonitrile, and 3-(2-Nitro-phenylsulfanyl)-1-pyridin-2-ylmethyl-1H-indole-6-carbonitrile-hydrochloride, ~~3-(2-Nitro-phenylsulfanyl)-1-pyrimidin-5-ylmethyl-1H-indole-6-carbonitrile, 3-(2-Nitro-phenylsulfanyl)-1-pyrimidin-4-ylmethyl-~~

~~1*H*-indole-6-carbonitrile, *N* [1-(3,5-Difluoro-benzyl)-3-(2-nitro-phenylsulfanyl)-1*H*-indol-6-yl]-2-fluoro-acetamide, and *N* [3-(2-Nitro-phenylsulfanyl)-1-pyrimidin-5-ylmethyl-1*H*-indol-6-yl]-formamide.~~

10. (Currently Amended) The compound according to claim 5, wherein,

X is S;

R<sup>1</sup> is ~~3,5-difluorophenyl~~, pyridin-2-yl, or pyridin-3-yl, ~~3-fluorophenyl, 3-cyanophenyl, or 3-nitrophenyl~~;

R<sup>2</sup> is 2-nitrophenyl, 2-hydroxymethyl-phenyl, 2-methoxyphenyl, or 2-cyanophenyl ~~or pyridin-2-yl~~;

R<sup>3</sup> is H;

R<sup>5</sup> is C(O)N(R<sup>8</sup>,R<sup>9</sup>), wherein R<sup>8</sup> is H, and R<sup>9</sup> is H, or CH<sub>2</sub>R<sup>10</sup>, wherein R<sup>10</sup> is H, (1C-2C)alkyl, hydroxy(1C-2C)alkyl, or methoxy(1C-2C)alkyl.

11. (Currently Amended) The compound according to claim 10, wherein,

R<sup>1</sup> is ~~3,5-difluorophenyl~~, pyridin-2-yl, or pyridin-3-yl;

R<sup>2</sup> is 2-nitrophenyl, or 2-hydroxymethyl-phenyl;

R<sup>5</sup> is C(O)N(R<sup>8</sup>,R<sup>9</sup>), wherein R<sup>8</sup> is H, and R<sup>9</sup> is CH<sub>2</sub>R<sup>10</sup>, wherein R<sup>10</sup> is H, or (1C-2C)alkyl.

12. (Withdrawn) The compound according to claim 11, which is 1-(3,5-Difluoro-benzyl)-3-(2-nitro-phenylsulfanyl)-1*H*-indole-6-carboxylic acid methylamide.

13. (Currently Amended) The compound according to claim 4, wherein,

X is S;

R<sup>1</sup> is ~~3,5-difluorophenyl~~, pyridin-2-yl, or pyridin-3-yl, ~~3-fluorophenyl~~, ~~3-cyanophenyl~~, ~~or~~ ~~3-nitrophenyl~~;

R<sup>2</sup> is 2-nitrophenyl, 2-hydroxymethyl-phenyl, 2-methoxyphenyl, or 2-cyanophenyl ~~or pyridin-2-yl~~;

R<sup>3</sup> is H;

R<sup>5</sup> is C(O)N(R<sup>8</sup>,R<sup>9</sup>), wherein R<sup>8</sup> and R<sup>9</sup> each independently are H, or CH<sub>2</sub>R<sup>10</sup>, wherein R<sup>10</sup> is H, (1C-5C)alkyl, (1C-5C)alkenyl, hydroxy(1C-3C)alkyl, (1C-3C)alkoxy(1C-3C)alkyl, or (mono- or di(1C-4C)alkyl)aminomethyl.

14. (Currently Amended) The compound according to claim 13, wherein,

R<sup>1</sup> is ~~3,5-difluorophenyl~~, pyridin-2-yl, or pyridin-3-yl;

R<sup>2</sup> is 2-nitrophenyl, or 2-hydroxymethyl-phenyl;

R<sup>5</sup> is C(O)N(R<sup>8</sup>,R<sup>9</sup>), wherein R<sup>8</sup> and R<sup>9</sup> each independently are H, or CH<sub>2</sub>R<sup>10</sup>, wherein R<sup>10</sup> is H, (1C-5C)alkyl, hydroxy(1C-3C)alkyl, or (1C-3C)alkoxy(1C-3C)alkyl.

15. (Withdrawn) The compound according to claim 14, which is 1-(3,5-Difluoro-benzyl)-3-(2-nitrophenylsulfanyl)-1*H*-indole-6-carboxylic acid dimethylamide.

16. (Canceled).

17. (Previously Presented) A pharmaceutical composition, comprising:

the compound according to claim 1 or salt thereof and a pharmaceutically acceptable carrier.

18. (Currently Amended) A method of treating ~~an androgen receptor related disorder~~ benign prostate hyperplasia in a patient in need thereof, comprising:

administering to said patient a pharmaceutically effective amount of the compound or salt thereof according to claim 1.

19. (Cancelled)

20. (Withdrawn) A method of treating an androgen insufficiency, comprising:

administering a pharmaceutically effective amount of the compound according to to claim 1 to a subject in need thereof.

21. (Cancelled).